Literature DB >> 28682481

Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.

Sarah Moody1, Leire Escudero-Ibarz1, Ming Wang1, Alexandra Clipson1, Eguzkine Ochoa Ruiz1, Deborah Dunn-Walters2, Xuemin Xue1, Naiyan Zeng1, Alistair Robson3, Shih-Sung Chuang4, Sergio Cogliatti5, Hongxiang Liu6, John Goodlad7, Margaret Ashton-Key8, Markus Raderer9, Yingwen Bi1,10, Ming-Qing Du1,6,11.   

Abstract

Both antigenic drive and genetic change play critical roles in the development of mucosa-associated lymphoid tissue (MALT) lymphoma, but neither alone is sufficient for malignant transformation, and lymphoma development critically depends on their cooperation. However, which of these different events concur and how they cooperate in MALT lymphomagenesis is totally unknown. To explore this, we investigated somatic mutations of 17 genes and immunoglobulin heavy chain variable region (IGHV) usage in 179 MALT lymphomas from various sites. We showed that: (1) there was a significant association between the biased usage of IGHV4-34 (binds to the carbohydrate I/i antigens) and inactivating mutation of TNFAIP3 [encoding a global negative regulator of the canonical nuclear factor-κB (NF-κB) pathway] in ocular adnexal MALT lymphoma; (2) IGHV1-69 was significantly overrepresented (54%) in MALT lymphoma of the salivary gland, but was not associated with mutation in any of the 17 genes investigated; and (3) MALT lymphoma lacked mutations that are frequently seen in other B-cell lymphomas characterized by constitutive NF-κB activities, including mutations in CD79B, CARD11, MYD88, TNFRSF11A, and TRAF3. Our findings show, for the first time, a significant association between biased usage of autoreactive IGHV and somatic mutation of NF-κB regulators in MALT lymphoma, arguing for their cooperation in sustaining chronic B-cell receptor signalling and driving oncogenesis in lymphoma development.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  IGHV usage; MALT lymphoma; NF-κB; TNFAIP3 mutation

Mesh:

Substances:

Year:  2017        PMID: 28682481     DOI: 10.1002/path.4933

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up.

Authors:  Helen Parker; Neil Robert McIver-Brown; Zadie A Davis; Marina Parry; Matthew J J Rose-Zerilli; Aliki Xochelli; Jane Gibson; Renata Walewska; Jonathan C Strefford; David G Oscier
Journal:  Blood Adv       Date:  2018-05-22

Review 2.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Authors:  Rita Alaggio; Catalina Amador; Ioannis Anagnostopoulos; Ayoma D Attygalle; Iguaracyra Barreto de Oliveira Araujo; Emilio Berti; Govind Bhagat; Anita Maria Borges; Daniel Boyer; Mariarita Calaminici; Amy Chadburn; John K C Chan; Wah Cheuk; Wee-Joo Chng; John K Choi; Shih-Sung Chuang; Sarah E Coupland; Magdalena Czader; Sandeep S Dave; Daphne de Jong; Ming-Qing Du; Kojo S Elenitoba-Johnson; Judith Ferry; Julia Geyer; Dita Gratzinger; Joan Guitart; Sumeet Gujral; Marian Harris; Christine J Harrison; Sylvia Hartmann; Andreas Hochhaus; Patty M Jansen; Kennosuke Karube; Werner Kempf; Joseph Khoury; Hiroshi Kimura; Wolfram Klapper; Alexandra E Kovach; Shaji Kumar; Alexander J Lazar; Stefano Lazzi; Lorenzo Leoncini; Nelson Leung; Vasiliki Leventaki; Xiao-Qiu Li; Megan S Lim; Wei-Ping Liu; Abner Louissaint; Andrea Marcogliese; L Jeffrey Medeiros; Michael Michal; Roberto N Miranda; Christina Mitteldorf; Santiago Montes-Moreno; William Morice; Valentina Nardi; Kikkeri N Naresh; Yasodha Natkunam; Siok-Bian Ng; Ilske Oschlies; German Ott; Marie Parrens; Melissa Pulitzer; S Vincent Rajkumar; Andrew C Rawstron; Karen Rech; Andreas Rosenwald; Jonathan Said; Clémentine Sarkozy; Shahin Sayed; Caner Saygin; Anna Schuh; William Sewell; Reiner Siebert; Aliyah R Sohani; Reuben Tooze; Alexandra Traverse-Glehen; Francisco Vega; Beatrice Vergier; Ashutosh D Wechalekar; Brent Wood; Luc Xerri; Wenbin Xiao
Journal:  Leukemia       Date:  2022-06-22       Impact factor: 12.883

3.  Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.

Authors:  Nabila Belhouachi; Aliki Xochelli; Myriam Boudjoghra; Claude Lesty; Nathalie Cassoux; Christine Fardeau; Thi Ha Chau Tran; Sylvain Choquet; Bishnu Sarker; Caroline Houillier; Agusti Alentorn; Phuc LeHoang; Carole Soussain; Valerie Touitou; Helene Merle-Beral; Khe Hoang-Xuan; Bahram Bodaghi; Kostas Stamatopoulos; Frederic Davi
Journal:  Blood Adv       Date:  2020-04-14

Review 4.  Recent advances in understanding the biology of marginal zone lymphoma.

Authors:  Francesco Bertoni; Davide Rossi; Emanuele Zucca
Journal:  F1000Res       Date:  2018-03-28

5.  Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites.

Authors:  Sarah Moody; Joe Sneath Thompson; Shih-Sung Chuang; Hongxiang Liu; Markus Raderer; George Vassiliou; Iwona Wlodarska; Fangtian Wu; Sergio Cogliatti; Alistair Robson; Margaret Ashton-Key; Yingwen Bi; John Goodlad; Ming-Qing Du
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

Review 6.  The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies.

Authors:  Francesca Arruga; Tiziana Vaisitti; Silvia Deaglio
Journal:  Front Oncol       Date:  2018-11-26       Impact factor: 6.244

Review 7.  MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.

Authors:  Ruben A L de Groen; Anne M R Schrader; Marie José Kersten; Steven T Pals; Joost S P Vermaat
Journal:  Haematologica       Date:  2019-11-07       Impact factor: 9.941

Review 8.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to August 2017.

Authors:  J H van Krieken
Journal:  J Hematop       Date:  2017-09-30       Impact factor: 0.196

9.  High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.

Authors:  V Pillonel; D Juskevicius; C K Y Ng; A Bodmer; A Zettl; D Jucker; S Dirnhofer; A Tzankov
Journal:  Leukemia       Date:  2018-02-28       Impact factor: 11.528

Review 10.  B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making.

Authors:  Katerina Gemenetzi; Andreas Agathangelidis; Laura Zaragoza-Infante; Electra Sofou; Maria Papaioannou; Anastasia Chatzidimitriou; Kostas Stamatopoulos
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.